PharmaCyte Biotech (PMCB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.34, -4.81% vs the prior close of $0.36.
- Volume 32.98K shares, 0.2x its 50-day average (light).
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
PMCB slides 4.8% to $0.34, a 52-week low. Closed at $0.34, -4.81% vs the prior close of $0.36. Day range $0.34–$0.36, opened at $0.35.
PMCB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PMCB slides 4.8% to $0.34, a 52-week low
- Closed at $0.34, -4.81% vs the prior close of $0.36. Day range $0.34–$0.36, opened at $0.35.
- Volume was 32.98K shares, 0.2x its 50-day average of 219.31K — lighter than usual.
- Price is -26.3% vs its 50-day average ($0.46) and -49.2% vs its 200-day average ($0.67).
- 52-week range $0.33–$1.51; today's close sits at 1% of that range, 77.5% below the 52-week high.
Oct 15, 2026 — PMCB rises 2.6% to $0.36
- Closed at $0.36, +2.55% vs the prior close of $0.35. Day range $0.34–$0.36, opened at $0.34.
- Volume was 54.10K shares, 0.2x its 50-day average of 218.68K — lighter than usual.
- Price is -23.5% vs its 50-day average ($0.47) and -46.7% vs its 200-day average ($0.67).
- 52-week range $0.33–$1.51; today's close sits at 2% of that range, 76.3% below the 52-week high.
Oct 14, 2026 — PMCB dips 2.1% to $0.35, a 52-week low, 3 down days in a row
- Closed at $0.35, -2.08% vs the prior close of $0.36. Day range $0.34–$0.37, opened at $0.36.
- Volume was 40.40K shares, 0.2x its 50-day average of 223.02K — lighter than usual.
- Price is -26.1% vs its 50-day average ($0.47) and -48.2% vs its 200-day average ($0.67).
- 52-week range $0.33–$1.51; today's close sits at 1% of that range, 76.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PMCB dips 2.5% to $0.36, a 52-week low
- Closed at $0.36, -2.52% vs the prior close of $0.37. Day range $0.35–$0.37, opened at $0.36.
- Volume was 61.40K shares, 0.3x its 50-day average of 224.42K — lighter than usual.
- Price is -25.3% vs its 50-day average ($0.48) and -47.3% vs its 200-day average ($0.67).
- 52-week range $0.33–$1.51; today's close sits at 2% of that range, 76.4% below the 52-week high.
Oct 12, 2026 — PMCB slides 9.7% to $0.37, a 52-week low
- Closed at $0.37, -9.72% vs the prior close of $0.40. Day range $0.36–$0.40, opened at $0.39.
- Volume was 116.90K shares, 0.5x its 50-day average of 225.20K — lighter than usual.
- Price is -24.1% vs its 50-day average ($0.48) and -46.1% vs its 200-day average ($0.68).
- 52-week range $0.33–$1.51; today's close sits at 3% of that range, 75.8% below the 52-week high.
Oct 9, 2026 — PMCB rises 1.8% to $0.40
- Closed at $0.40, +1.76% vs the prior close of $0.40. Day range $0.39–$0.41, opened at $0.41.
- Volume was 93.50K shares, 0.4x its 50-day average of 235.89K — lighter than usual.
- Price is -16.7% vs its 50-day average ($0.49) and -40.4% vs its 200-day average ($0.68).
- 52-week range $0.33–$1.51; today's close sits at 6% of that range, 73.2% below the 52-week high.
Oct 8, 2026 — PMCB dips 2.0% to $0.40
- Closed at $0.40, -2.02% vs the prior close of $0.41. Day range $0.39–$0.42, opened at $0.41.
- Volume was 214.10K shares, 0.9x its 50-day average of 232.54K.
- Price is -18.8% vs its 50-day average ($0.49) and -41.6% vs its 200-day average ($0.68).
- 52-week range $0.33–$1.51; today's close sits at 5% of that range, 73.7% below the 52-week high.
Oct 7, 2026 — PMCB slides 4.0% to $0.41
- Closed at $0.41, -3.98% vs the prior close of $0.42. Day range $0.40–$0.42, opened at $0.42.
- Volume was 97.50K shares, 0.4x its 50-day average of 232.84K — lighter than usual.
- Price is -17.7% vs its 50-day average ($0.49) and -40.6% vs its 200-day average ($0.68).
- 52-week range $0.33–$1.51; today's close sits at 6% of that range, 73.1% below the 52-week high.
Oct 6, 2026 — PMCB jumps 8.3% to $0.42
- Closed at $0.42, +8.28% vs the prior close of $0.39. Day range $0.39–$0.44, opened at $0.39.
- Volume was 232.10K shares, 1.0x its 50-day average of 230.97K.
- Price is -14.9% vs its 50-day average ($0.50) and -38.4% vs its 200-day average ($0.69).
- 52-week range $0.33–$1.51; today's close sits at 8% of that range, 72.0% below the 52-week high.
Oct 5, 2026 — PMCB dips 2.5% to $0.39, 7 down days in a row
- Closed at $0.39, -2.50% vs the prior close of $0.40. Day range $0.39–$0.41, opened at $0.40.
- Volume was 73.60K shares, 0.3x its 50-day average of 231.14K — lighter than usual.
- Price is -22.0% vs its 50-day average ($0.50) and -43.3% vs its 200-day average ($0.69).
- 52-week range $0.33–$1.51; today's close sits at 5% of that range, 74.2% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — PMCB dips 0.9% to $0.40, 6 down days in a row
- Closed at $0.40, -0.94% vs the prior close of $0.40. Day range $0.40–$0.42, opened at $0.41.
- Volume was 41.70K shares, 0.2x its 50-day average of 232.65K — lighter than usual.
- Price is -20.6% vs its 50-day average ($0.50) and -42.0% vs its 200-day average ($0.69).
- 52-week range $0.33–$1.51; today's close sits at 6% of that range, 73.5% below the 52-week high.
- That makes 6 straight losses.
PMCB latest news & SEC filings
Every SEC filing by or about PMCB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 4.01 — Changed its outside auditor.
Sep 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jul 31, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$5.08M (prior year -$8.36M) (loss narrowed vs Jul 31, 2025)
- Diluted EPS: -$0.54 (prior year -$1.23) (loss narrowed vs Jul 31, 2025)
Jul 29, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Apr 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: -$19.42M (prior year $30.66M) (loss widened vs Apr 30, 2025)
- Diluted EPS: -$2.77 (prior year $3.19) (loss widened vs Apr 30, 2025)
Jul 17, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade PMCB
- Last results release: Jul 11, 2022 (8-K Item 2.02).
- How much it moves: over the last 20 sessions the average daily move was 3.49% (largest 9.7%). That is a volatile stock.
- Liquidity: about 135.65K shares (≈$46.15K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.34 vs a range of $0.33–$1.51 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 24 open-market buys, 0 sales; latest: Joshua Silverman bought 40,000 shares on Jan 7, 2026.
- Latest filings: 8-K Oct 16, 2026; 10-Q Sep 14, 2026; 10-K Jul 29, 2026.
- Share count: 10.74M shares outstanding (Sep 11, 2026), +58.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
PMCB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.35 | 0.36 | 0.34 | 0.34 | 32.98K |
| Oct 15, 2026 | 0.34 | 0.36 | 0.34 | 0.36 | 54.10K |
| Oct 14, 2026 | 0.36 | 0.37 | 0.34 | 0.35 | 40.40K |
| Oct 13, 2026 | 0.36 | 0.37 | 0.35 | 0.36 | 61.40K |
| Oct 12, 2026 | 0.39 | 0.40 | 0.36 | 0.37 | 116.90K |
| Oct 9, 2026 | 0.41 | 0.41 | 0.39 | 0.40 | 93.50K |
| Oct 8, 2026 | 0.41 | 0.42 | 0.39 | 0.40 | 214.10K |
| Oct 7, 2026 | 0.42 | 0.42 | 0.40 | 0.41 | 97.50K |
| Oct 6, 2026 | 0.39 | 0.44 | 0.39 | 0.42 | 232.10K |
| Oct 5, 2026 | 0.40 | 0.41 | 0.39 | 0.39 | 73.60K |
| Oct 2, 2026 | 0.41 | 0.42 | 0.40 | 0.40 | 41.70K |
| Oct 1, 2026 | 0.42 | 0.44 | 0.40 | 0.40 | 82.70K |
| Sep 30, 2026 | 0.42 | 0.44 | 0.41 | 0.41 | 193.30K |
| Sep 29, 2026 | 0.43 | 0.45 | 0.42 | 0.42 | 110.80K |
| Sep 28, 2026 | 0.44 | 0.44 | 0.41 | 0.42 | 140.30K |
| Sep 25, 2026 | 0.45 | 0.47 | 0.44 | 0.44 | 399.50K |
| Sep 24, 2026 | 0.43 | 0.47 | 0.43 | 0.46 | 288.60K |
| Sep 23, 2026 | 0.44 | 0.46 | 0.42 | 0.43 | 241.00K |
| Sep 22, 2026 | 0.44 | 0.46 | 0.44 | 0.46 | 98.10K |
| Sep 21, 2026 | 0.46 | 0.46 | 0.44 | 0.45 | 100.50K |
About PharmaCyte Biotech
PharmaCyte Biotech (PMCB) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in LAS VEGAS, NV. State of incorporation: NV. Fiscal year ends April 30. SEC CIK 1157075.
PMCB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael M Abecassis | Director | Jul 17, 2026 |
| Jonathan Schechter | Director | Jul 17, 2026 |
| Joshua Silverman | CEO and President | Jan 7, 2026 |
| Wayne Remell Walker | Director | Jul 17, 2026 |
| Robert Weinstein | Director | Jul 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Joshua Silverman | CEO and President | Jan 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jan 7, 2026 | Joshua Silverman | Buy | 40,000 | $0.83 |
| Jan 7, 2026 | Joshua Silverman | Buy | 40,000 | $0.83 |
| Jan 7, 2026 | Joshua Silverman | Buy | 40,000 | $0.83 |
| Jan 7, 2026 | Joshua Silverman | Buy | 40,000 | $0.83 |
| Jan 7, 2026 | Jonathan Schechter | Buy | 20,000 | $0.84 |
| Jan 7, 2026 | Jonathan Schechter | Buy | 20,000 | $0.84 |
| Jan 7, 2026 | Jonathan Schechter | Buy | 20,000 | $0.84 |
| Jan 7, 2026 | Jonathan Schechter | Buy | 20,000 | $0.84 |
| Jan 6, 2026 | Joshua Silverman | Buy | 30,000 | $0.79 |
| Jan 6, 2026 | Joshua Silverman | Buy | 30,000 | $0.79 |
| Jan 6, 2026 | Joshua Silverman | Buy | 30,000 | $0.79 |
| Jan 6, 2026 | Joshua Silverman | Buy | 30,000 | $0.79 |
| Jan 6, 2026 | Jonathan Schechter | Buy | 20,000 | $0.79 |
| Jan 6, 2026 | Jonathan Schechter | Buy | 20,000 | $0.79 |
| Jan 6, 2026 | Jonathan Schechter | Buy | 20,000 | $0.79 |
PMCB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Apr 30, 2026 | $0 | $-19.42M | -2.77 | $-5.15M |
| Apr 30, 2025 | $0 | $30.66M | 3.19 | $-2.98M |
| Apr 30, 2024 | $0 | $333.76K | -1.80 | $-2.15M |
| Apr 30, 2023 | $0 | $-4.32M | -0.22 | $-3.79M |
| Apr 30, 2022 | $0 | $-4.24M | -0.27 | $-4.12M |
Latest balance sheet: total assets $36.71M, total liabilities $6.90M, cash $17.74M (as of Jul 31, 2026).
PMCB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 11, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PMCB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.